CD8A and pancreatic neuroendocrine tumor: However, a bispecific approach with PD1-IL2v to expand stem cells like CD8+ T cells and anti-PD-L1 to reprogram macrophages and vasculature in immunotherapy-resistant pancreatic neuroendocrine tumors in RIP1-Tag5 mouse model showed complete tumor regression (6).